CA-RUBRYC-THERAPEUTICS
14.4.2021 02:02:10 CEST | Business Wire | Press release
RubrYc Therapeutics, Inc., a pre-clinical biotherapeutics company developing epitope selective therapies, today announced that it has entered into a research collaboration and license option agreement with Zai Labs, Inc. for the use of RubrYc’s Meso-scale Engineered Molecules (MEMs) platform, to identify monoclonal antibodies with enhanced biological function for an undisclosed oncology target.
Under the terms of the agreement RubrYc and Zai Labs will collaborate to identify product candidates using RubrYc’s Discovery Engine, which leverages machine learning and structural data to identify antibodies that bind to subdominant epitopes and exhibit differentiated activity. Upon exercise of the license option Zai Labs would have exclusive global rights to develop and commercialize product(s) of the Research Collaboration.
RubrYc Therapeutics, Inc. will receive an upfront payment and is eligible to receive future research, development and commercialization milestones on a per candidate basis, along with royalties on world-wide net sales of each product. Financial terms of the agreement were not disclosed.
Dr. Isaac Bright, CEO, said, “We are excited that Zai Labs has selected the RubrYc Discovery Engine as part of its efforts to identify biotherapeutics against challenging oncology targets. We look forward to collaborating with Zai Labs to accelerate their research by identifying epitope-specific antibodies with differentiated modes of action. Zai Labs’ oncology expertise complements our interest in bringing novel therapeutics with breakthrough potential to patients in need.”
About RubrYc Therapeutics, Inc.
RubrYc Therapeutics, Inc., is a biotechnology company applying proprietary machine-learning and computational biology solutions to discover epitope-selective mono and bispecific antibodies. Inspired by recent advances in molecular library synthesis, massively parallel screening and computing, RubrYc is forging a new path for information-driven discovery of therapeutic antibodies. RubrYc Therapeutics, Inc. leverages the MEMs Discovery Engine technology to rapidly identify large numbers of antibodies with unique binding properties against validated and challenging targets. RubrYc spun out of HealthTell, Inc. in 2018 to advance discovery of biotherapeutics, and to partner with top-tier pharmaceutical companies that share our mission to expand therapeutic options and improve outcomes for cancer patients. RubrYc is backed by institutional investors, including Third Point Ventures, Paladin Capital Group, Vital Venture Capital, and Hayan Health Networks. The Company is based in San Carlos, California.
For more information, visit www.rubryc.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413006012/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Navan Unlocks Savings for Travelers with First SAS NDC Direct Connect28.5.2026 09:01:00 CEST | Press release
Direct connection gives travelers access to lower fares and streamlined post-booking services Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced a New Distribution Capability (NDC) integration with Scandinavian Airlines (SAS). By allowing the airline to share its fares, availability, and offers directly in real time, the integration provides an expanded portfolio of SAS fares and services to Navan customers. This makes Navan the first Travel Management Company (TMC) to access SAS NDC content via a direct connection, leveraging version 21.3 of the NDC API. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260528812727/en/ Direct connection gives travelers access to lower fares and streamlined post-booking services “Our Modern Airline Retailing journey is centered on delivering more relevant offers, greater transparency, and better value for travelers,” said Edward Fotheringham, VP S
KKR to Open New Office in Milan, Strengthening Long-Term Commitment to Italy28.5.2026 09:00:00 CEST | Press release
New office reflects KKR’s localisation strategy and opportunity in Italy’s evolving investment landscape KKR, a leading global investment firm, today announced plans to open an office in Milan, further strengthening its long-term commitment to Italy and expanding its local presence in one of Europe’s largest economies. The office will support the firm’s investment activity across Private Equity, Real Assets, Credit and Insurance, while deepening client partnerships and advancing the continued development of KKR’s private wealth business in Italy. Italy has been an important market for KKR for over two decades, with over €10 billion of capital deployed since 2005 across Private Equity, Real Assets and Credit. The firm’s investments include FiberCop, Europe’s first wholesale-only, open-access fibre network, Enilive, a key player in advancing Italy’s energy transition, and CMC, a sustainable packaging leader using robotics to drive innovation. These investments reflect KKR’s focus on part
Merz Therapeutics Presents New Research at World Parkinson Congress 2026, Revealing the Hidden Burden of "OFF" Episodes in Parkinson’s Disease28.5.2026 09:00:00 CEST | Press release
A new qualitative literature review provides a comprehensive model of the patient experience of OFF episodes, identifying 132 distinct motor, non-motor and quality-of-life impacts1 The research highlights OFF episode as a complex, multifaceted experience, highlighting the profound and often invisible struggles faced by people with Parkinson’s disease1 Additional analyses of levodopa inhalation powder (INBRIJA®) confirm its clinical profile as a rapid, reliable and well-tolerated on-demand treatment for OFF episodes2,3 Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new research at the World Parkinson Congress (WPC) 2026 that uncovers the multifaceted burden of "OFF" episodes in Parkinson's disease (PD). The qualitative literature review demonstrates that these episodes are not only a re-emergence of motor symptoms, but also a complex mix of debilitating motor and non-motor symptoms that impact the lives of people with Parki
Navan Strengthens European Train Offering with Swedish Rail Integration28.5.2026 09:00:00 CEST | Press release
Through a direct connection with SilverRail, Navan adds more than 20 Swedish rail carriers to its long list of European rail options Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced the addition of more than 20 Swedish rail carriers to its platform, including Sweden’s largest operators, SJ and VR. Powered by SilverRail's global rail distribution platform, the API integration unlocks access for Navan customers to domestic rail routes in Sweden, as well as many popular cross-border routes in the region, such as between Stockholm and Copenhagen. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260528696890/en/ Through a direct connection with SilverRail, Navan adds more than 20 Swedish rail carriers to its long list of European rail options “We’re seeing strong momentum in Sweden,” says Michael Riegel, Chief Customer Officer at Navan. “It’s a unique economy where you have this inte
SMBC and Toshiba Jointly Develop New Equity Indices Using Advanced Quantum-Driven Technologies28.5.2026 03:00:00 CEST | Press release
Sumitomo Mitsui Banking Corporation (“SMBC”) and Toshiba Corporation (“Toshiba”) today announced the joint development of the SMBC/TOSHIBA Quantum Driven Diversified Japan Equity Index and the SMBC/TOSHIBA Quantum Driven Diversified U.S. Equity Index, new equity indices realized with advanced quantum-driven technologies. Collectively, the indices are referred to as “SMBC/TOSHIBA Quantum Diversified” (the “Indices”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519448161/en/ Toshiba’s Simulated Bifurcation Machine 1. Background and Objectives Equity investment is central to asset management, but it also carries the ever-present risk of abrupt and substantial market fluctuations driven by geopolitical developments, changes in economic policy, and other external factors. In uncertain markets, investors are constantly seeking innovations in risk diversification that can protect their assets from unexpected market shocks. SM
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom